These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
138 related items for PubMed ID: 22531308
1. Quality of life of methylphenidate treatment-responsive adolescents with attention-deficit/hyperactivity disorder. Yang PC, Lung FW, Chiou SS, Yen CF, Fuh JL. Kaohsiung J Med Sci; 2012 May; 28(5):279-84. PubMed ID: 22531308 [Abstract] [Full Text] [Related]
2. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample. Yang P, Hsu HY, Chiou SS, Chao MC. Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272 [Abstract] [Full Text] [Related]
3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study. Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK. Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731 [Abstract] [Full Text] [Related]
4. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B. Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084 [Abstract] [Full Text] [Related]
5. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial. Gerwe M, Stollhoff K, Mossakowski J, Kuehle HJ, Goertz U, Schaefer C, Bogdanow M, Heger S. Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582 [Abstract] [Full Text] [Related]
6. A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits. Leitner Y, Doniger GM, Barak R, Simon ES, Hausdorff JM. J Child Neurol; 2007 Mar; 22(3):264-76. PubMed ID: 17621495 [Abstract] [Full Text] [Related]
7. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Fallu A, Richard C, Prinzo R, Binder C. Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338 [Abstract] [Full Text] [Related]
8. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Yoo HK, Park S, Wang HR, Lee JS, Kim K, Paik KW, Yum MS, Ko TS. Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067 [Abstract] [Full Text] [Related]
9. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B. Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923 [Abstract] [Full Text] [Related]
10. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. Gürkan K, Bilgiç A, Türkoglu S, Kiliç BG, Aysev A, Uslu R. J Psychopharmacol; 2010 Dec; 24(12):1810-8. PubMed ID: 19939861 [Abstract] [Full Text] [Related]
11. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B. Curr Med Res Opin; 2011 Dec; 27 Suppl 2():35-44. PubMed ID: 21787126 [Abstract] [Full Text] [Related]
12. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial. Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S. J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402 [Abstract] [Full Text] [Related]
13. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder. Cox DJ, Davis M, Mikami AY, Singh H, Merkel RL, Burket R. J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664 [Abstract] [Full Text] [Related]
14. Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD. Gadow KD, Nolan EE. J Atten Disord; 2011 Apr; 15(3):246-56. PubMed ID: 20378921 [Abstract] [Full Text] [Related]
15. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H. Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386 [Abstract] [Full Text] [Related]
16. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD. Flapper BC, Schoemaker MM. Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997 [Abstract] [Full Text] [Related]
17. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Klassen AF, Miller A, Fine S. Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087 [Abstract] [Full Text] [Related]